Three Overlooked AI Stocks with Multibagger Potential: A Deep Dive

1. Teradine – The Robot Testing Powerhouse

Whenever I hear the name Teradine, I can’t help but think of Aero Industries from The Wolf of Wall Street. But unlike that fictional company, Teradine is the real deal. They specialize in high-tech robot testing machines that act as super smart inspectors, ensuring that products are flawless before hitting the market. Additionally, they manufacture robots for factories, helping with tasks like heavy lifting and assembly.

AI plays a central role in Teradine’s operations. For their testing machines, AI acts as a brilliant problem-solver, quickly identifying errors in chips or electronics by learning patterns and spotting issues that human inspectors might miss. These machines collect vast amounts of data, which AI analyzes to predict potential failures before they occur, saving companies from costly downtimes.

For their robots, AI serves as the brain, enabling them to learn and adapt to their environments. Instead of being pre-programmed for specific tasks, Teradine’s robots can observe, practice, and learn new tasks quickly. AI also enhances efficiency by predicting when maintenance is needed, thereby preventing unexpected breakdowns.

Stock Analysis

Currently, Teradine is a $2 billion company with an enterprise value of around $20 billion, implying net debt is nearly zero. Their 5-year return on invested capital (ROIC) stands at an impressive 19%. However, they have a PE ratio of 39 and a price-to-free-cash-flow (P/FCF) ratio of 44. These metrics may seem high, but they could be justified if the company’s growth prospects pan out. Think about Nvidia when it was trading at $100 before the split—it looked expensive, but those who believed in its potential were handsomely rewarded.

Looking at Teradine’s eight pillars, it’s a mixed bag with five Xs and three checks. Revenue, net income, and free cash flow have all declined over the past five years, raising some concerns. However, quarterly data shows potential signs of a rebound:

• Latest quarter revenue: $737 million (up from $703 million).
• Two quarters ago: $827 million.
• Last year’s quarter comparison: $730 million vs. $684 million.

Analyst projections are optimistic, forecasting earnings per share (EPS) of $3.20 in 2024 and $8.36 by 2028—a potential 2.5x increase. Revenue is expected to grow from $2.8 billion to $4.7 billion in the same period.

Stock Analyzer Tool Assumptions:

• Revenue growth: 3%, 6%, and 9%.
• Profit margin: 17%, 19%, and 21%.
• Free cash flow margin: Same as profit margin.
• PE ratio: 14, 18, and 22.
• Desired return: 9%.

Based on these assumptions, the stock appears overvalued, with a low-end valuation of $42, a high-end valuation of $108, and a middle value of $68. With the current stock price at $120, it feels pricey unless you have a more optimistic outlook.

2. Tempus AI Inc. – The Healthcare Data Giant

Tempus AI is another fascinating company, boasting a name that directly reflects its focus on artificial intelligence. Over the past few years, they have experienced rapid growth, with revenue increasing by about 30% annually. Analysts project that their revenue will exceed $4 million by 2025, driven by their expanding partnerships in healthcare and pharmaceuticals.

Tempus has built one of the world’s largest healthcare data repositories, processing over 50 petabytes of medical information. To put that into perspective, one petabyte equals 1,000 terabytes. Tempus collaborates with over 50% of the top global pharmaceutical companies, accelerating drug discovery and clinical trials. Their AI solutions have helped reduce participant identification time for clinical trials by up to 50%, drastically speeding up the drug development process.

Stock Analysis

Tempus has a market cap of $7.55 billion and an enterprise value of $8 billion. However, they currently have negative free cash flow, which makes them a riskier investment. While they’ve been public for a relatively short time and have decreased shares outstanding by 0.5%, sustained negative cash flow could force them to issue more shares or take on debt in the future.

Given their current metrics, it’s challenging to analyze Tempus using the stock analyzer tool. If you have a deep understanding of this company and its potential path to profitability, it might be worth a closer look. However, for most investors, it requires additional research and analysis.

3. EPAM Systems – The Digital Transformation Leader

EPAM Systems isn’t just another tech company—it’s a leader in digital innovation. From developing cutting-edge websites and apps to offering expert consulting services, EPAM helps businesses modernize their operations across various industries. Their clients include some of the biggest names in healthcare, finance, and telecom. They’ve even collaborated with the IMF to launch Stat GPT 2.0, a groundbreaking AI platform that makes global economic data more accessible.

Stock Analysis

EPAM reached an all-time high of $725 per share in November 2021 but has since fallen to a recent low of $169. With a market cap of $14.2 billion and an enterprise value of $13 billion, they have more cash than debt on their books. Despite a modest gross margin of 31%, they generate solid free cash flow, which is currently higher than their net income.

EPAM’s eight pillars show six checks and two Xs, with the negatives being valuation-related. Analyst estimates suggest 40% EPS growth over the next four years, with revenue growing from $4.78 billion to $6.48 billion. While these growth rates aren’t mind-blowing, they’re steady, and the company’s solid financials make it a compelling investment.

Stock Analyzer Tool Assumptions:

• Revenue growth: 3%, 6%, and 9%.
• Profit margin: 9.5%, 10%, and 11%.
• Free cash flow margin: Slightly higher than profit margin.
• PE ratio: 14, 17, and 20.
• Desired return: 9%.

The tool estimates a low-end valuation of $113 to $120, a high-end range of $260 to $280, and a middle range of $170 to $180. With the stock trading at $247, it’s currently a “wait and watch” situation.

Final Thoughts

These three AI stocks—Teradine, Tempus AI, and EPAM Systems—offer exciting opportunities but come with varying degrees of risk. If you’re intrigued by any of these companies, dive deeper, do your research, and, if possible, join a community of like-minded investors to exchange insights. And if you’re interested in using advanced tools to analyze stocks like we did, check out the software we offer. It might just be one of the best decisions you make this year!

Everything Money is Not an Investment Advisor: Everything Money (including Paul, Mo, and Any other person including, but not limited to, other staff members, guests, personalities, etc.) is not an investment adviser, and it is not registered as such with the U.S. Securities & Exchange Commission or any other state or federal authority under the Investment Advisers Act of 1940 or any other law. The investments and strategies discussed in Everything Money’s YouTube videos and on Everythingmoney.com are not and should not be considered investment advice and may not be suitable for you. They do not take into account your particular investment objectives, financial situation, needs, or personal circumstances and are not intended to be specific to you. Before acting on any investment or strategy discussed, you should always do your own research and make your own independent decision about whether it is suitable for your particular circumstances. You should also consider seeking advice from your own legal, financial, tax, accounting, or investment advisers. Everything Money does not provide such advice.

READ THE FULL DISCLAIMER HERE: https://everythingmoney.com/disclaimer